Objectives: This multicentre study aimed to investigate the overall mortality of combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis (SSc) and to compare CPFE-SSc characteristics with those of other SSc subtypes (with interstitial lung disease - ILD, emphysema or neither). Methods: Chest CTs, anamnestic data, immunological profile and pulmonary function tests of patients with SSc were retrospectively collected. Each chest CT underwent a semiquantitative assessment blindly performed by three radiologists. Patients were clustered in four groups: SSc-CPFE, SSc-ILD, SSc-emphysema and other-SSc (without ILD nor emphysema). The overall mortality of these groups was calculated by Kaplan-Meier method and compared with the stratified log-rank test; Kruskal-Wallis test, t-Student test and χ 2 test assessed the differences between groups. P<0.05 was considered statistically significant. Results: We enrolled 470 patients (1959 patient-year); 15.5 % (73/470) died during the follow-up. Compared with the SSc-ILD and other-SSc, in SSc-CPFE there was a higher prevalence of males, lower anticentromere antibodies prevalence and a more reduced pulmonary function (p<0.05). The Kaplan-Meier survival analysis demonstrates a significantly worse survival in patients with SSc-CPFE (HR vs SSc-ILD, vs SSc-emphysema and vs other-SSc, respectively 1.6 (CI 0.5 to 5.2), 1.6 (CI 0.7 to 3.8) and 2.8 (CI 1.2 to 6.6). Conclusions: CPFE increases the mortality risk in SSc along with a highly impaired lung function. These findings strengthen the importance to take into account emphysema in patients with SSc with ILD.

Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis / Ariani, A.; Silva, M.; Bravi, E.; Parisi, S.; Saracco, M.; De Gennaro, F.; Caimmi, C.; Girelli, F.; De Santis, M.; Volpe, A.; Lumetti, F.; Hax, V.; Bredemeier, M.; Alfieri, V.; Santilli, D.; Bodini, F. C.; Lucchini, G.; Mozzani, F.; Seletti, V.; Bacchini, E.; Arrigoni, E.; Giuggioli, D.; Chakr, R.; Idolazzi, L.; Bertorelli, G.; Imberti, D.; Michieletti, E.; Paolazzi, G.; Fusaro, E.; Chetta, A. A.; Scire, C. A.; Sverzellati, N.. - In: RMD OPEN. - ISSN 2056-5933. - 5:1(2019), pp. e000820-e000820. [10.1136/rmdopen-2018-000820]

Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis

De Santis M.;Volpe A.;Lumetti F.;Alfieri V.;Lucchini G.;Giuggioli D.;Chetta A. A.;Sverzellati N.
2019

Abstract

Objectives: This multicentre study aimed to investigate the overall mortality of combined pulmonary fibrosis and emphysema (CPFE) in systemic sclerosis (SSc) and to compare CPFE-SSc characteristics with those of other SSc subtypes (with interstitial lung disease - ILD, emphysema or neither). Methods: Chest CTs, anamnestic data, immunological profile and pulmonary function tests of patients with SSc were retrospectively collected. Each chest CT underwent a semiquantitative assessment blindly performed by three radiologists. Patients were clustered in four groups: SSc-CPFE, SSc-ILD, SSc-emphysema and other-SSc (without ILD nor emphysema). The overall mortality of these groups was calculated by Kaplan-Meier method and compared with the stratified log-rank test; Kruskal-Wallis test, t-Student test and χ 2 test assessed the differences between groups. P<0.05 was considered statistically significant. Results: We enrolled 470 patients (1959 patient-year); 15.5 % (73/470) died during the follow-up. Compared with the SSc-ILD and other-SSc, in SSc-CPFE there was a higher prevalence of males, lower anticentromere antibodies prevalence and a more reduced pulmonary function (p<0.05). The Kaplan-Meier survival analysis demonstrates a significantly worse survival in patients with SSc-CPFE (HR vs SSc-ILD, vs SSc-emphysema and vs other-SSc, respectively 1.6 (CI 0.5 to 5.2), 1.6 (CI 0.7 to 3.8) and 2.8 (CI 1.2 to 6.6). Conclusions: CPFE increases the mortality risk in SSc along with a highly impaired lung function. These findings strengthen the importance to take into account emphysema in patients with SSc with ILD.
2019
5
1
e000820
e000820
Overall mortality in combined pulmonary fibrosis and emphysema related to systemic sclerosis / Ariani, A.; Silva, M.; Bravi, E.; Parisi, S.; Saracco, M.; De Gennaro, F.; Caimmi, C.; Girelli, F.; De Santis, M.; Volpe, A.; Lumetti, F.; Hax, V.; Bredemeier, M.; Alfieri, V.; Santilli, D.; Bodini, F. C.; Lucchini, G.; Mozzani, F.; Seletti, V.; Bacchini, E.; Arrigoni, E.; Giuggioli, D.; Chakr, R.; Idolazzi, L.; Bertorelli, G.; Imberti, D.; Michieletti, E.; Paolazzi, G.; Fusaro, E.; Chetta, A. A.; Scire, C. A.; Sverzellati, N.. - In: RMD OPEN. - ISSN 2056-5933. - 5:1(2019), pp. e000820-e000820. [10.1136/rmdopen-2018-000820]
Ariani, A.; Silva, M.; Bravi, E.; Parisi, S.; Saracco, M.; De Gennaro, F.; Caimmi, C.; Girelli, F.; De Santis, M.; Volpe, A.; Lumetti, F.; Hax, V.; Br...espandi
File in questo prodotto:
File Dimensione Formato  
e000820.full.pdf

Open access

Tipologia: Versione pubblicata dall'editore
Dimensione 342.43 kB
Formato Adobe PDF
342.43 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1222556
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 20
social impact